After a successful IPO on AIM, the AI-powered personal health consultant has launched its digital pharmacy services with AI-powered triage.
AI-powered personal health consultant MedPal AI has launched MedPal.clinic, its retail pharmacy website.
The clinic is a UK-first in digital pharmacy services, combining AI-powered triage with access to qualified independent prescribers and GPs, delivered through a multimodal communications platform. Users can access clinical consultations via their preferred communication method, including text messaging and WhatsApp.
“The launch of MedPal.clinic represents the culmination of our strategic vision to democratise healthcare access in the UK,” said chief executive Jason Drummond. “By combining our proprietary AI triage system with advanced robotic dispensing at our Swaffham facility, we have created a platform that eliminates the financial barrier to GP and independent prescriber consultations entirely,” he added.
The platform is initially targeting the UK weight-loss medication market, specifically GLP-1 agonist treatments, which, it says, represents a significant revenue opportunity. It is estimated that around 2.5 million UK adults are either currently using or intending to use GLP-1 drugs for weight loss. Given that private prescription costs average £150 to £200 per month, this represents a target addressable market exceeding £500 million in monthly revenue.
Efficiency gains
Companies like MedPal AI believe that the traditional pharmacy model presents challenges for users with regard to cost, convenience and accessibility. They want to address these through technology-driven efficiency gains and are targeting the weight-loss medication market, which is experiencing rapid growth in the UK and which is forecast to grow rapidly in the next few years.
MedPal AI’s route-to-market partnerships provide access to more than 11 million eligible employees via employee benefits technology provider Epassi UK and free initial access for members of more than 2,000 gyms through Independent Gyms, with revenue share arrangements on post-trial subscriptions. It is putting its faith in the company’s automated, AI-enhanced infrastructure, which delivers superior unit economics compared to traditional pharmacy models, enabling competitive pricing whilst maintaining clinical safety and quality standards.
MedPal AI raised £2 million when it listed on the AIM market at the end of August this year. The IPO gave the company a market capitalisation of £16.5 million, and its shares have almost doubled since then to 7.94 pence per share. Earlier this month, the firm announced its first NHS contract when Norfolk and Waveney ICB approved the change of ownership application of Universal’s NHS Distance Selling Pharmacy contract to MedPal.
